Second generation S1P pathway modulators: research strategies and clinical developments.
about
Sphingosine-1-Phosphate Receptor-2 Antagonists: Therapeutic Potential and Potential RisksFingolimod for the treatment of neurological diseases-state of play and future perspectivesIdentification of the phytosphingosine metabolic pathway leading to odd-numbered fatty acids.Exit Strategies: S1P Signaling and T Cell MigrationSphingosine 1 Phosphate at the Blood Brain Barrier: Can the Modulation of S1P Receptor 1 Influence the Response of Endothelial Cells and Astrocytes to Inflammatory Stimuli?Sphingosine-1-Phosphate Is a Novel Regulator of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) ActivityPathophysiological Consequences of a Break in S1P1-Dependent Homeostasis of Vascular Permeability Revealed by S1P1 Competitive AntagonismStructure-Activity Relationship Studies and Molecular Modeling of Naphthalene-Based Sphingosine Kinase 2 Inhibitors.Structure-activity relationship studies of the lipophilic tail region of sphingosine kinase 2 inhibitors.Drugging sphingosine kinases.Cardiac effects of amiselimod compared with fingolimod and placebo: results of a randomised, parallel-group, phase I study in healthy subjects.Sphingosine 1-phosphate signaling in bone remodeling: multifaceted roles and therapeutic potentialThe development and maintenance of paclitaxel-induced neuropathic pain require activation of the sphingosine 1-phosphate receptor subtype 1.Individual variation of human S1P₁ coding sequence leads to heterogeneity in receptor function and drug interactionsSwitching the sphingolipid rheostat in the treatment of diabetes and cancer comorbidity from a problem to an advantage.Biocomparison of Three Formulations of the S1P1 Receptor Modulator Ponesimod in Healthy Subjects.Sphingosine-1-phosphate and other lipid mediators generated by mast cells as critical players in allergy and mast cell functionDengue Virus-Induced Inflammation of the Endothelium and the Potential Roles of Sphingosine Kinase-1 and MicroRNAs.Sphingosine-1-phosphate in inflammatory bowel disease and colitis-associated colon cancer: the fat's in the fireNatural product and natural product derived drugs in clinical trials.2-Acetyl-5-tetrahydroxybutyl imidazole (THI) protects 661W cells against oxidative stress.Modulation of Neuroinflammation in the Central Nervous System: Role of Chemokines and Sphingolipids.Sphingolipids as targets for treatment of fungal infectionsTherapeutic potential of targeting sphingosine kinases and sphingosine 1-phosphate in hematological malignancies.Therapeutic Strategies and Pharmacological Tools Influencing S1P Signaling and Metabolism.Sphingosine 1-Phosphate Receptor 1 Signaling in Mammalian Cells.Effect of sphingosine kinase modulators on interleukin-1β release, sphingosine 1-phosphate receptor 1 expression and experimental autoimmune encephalomyelitis.Amiselimod, a novel sphingosine 1-phosphate receptor-1 modulator, has potent therapeutic efficacy for autoimmune diseases, with low bradycardia risk.Targeting sphingosine-1-phosphate signaling for cancer therapy.Dimethyl fumarate blocks pro-inflammatory cytokine production via inhibition of TLR induced M1 and K63 ubiquitin chain formation.Targeting the S1P/S1PR1 axis mitigates cancer-induced bone pain and neuroinflammation.Fingolimod (FTY720) enhances hippocampal synaptic plasticity and memory in Huntington's disease by preventing p75NTR up-regulation and astrocyte-mediated inflammation.Cerebral artery myogenic reactivity: The next frontier in developing effective interventions for subarachnoid hemorrhage.Pharmacokinetics, Pharmacodynamics, Tolerability, and Food Effect of Cenerimod, a Selective S1P₁ Receptor Modulator in Healthy Subjects.Absolute Bioavailability of Ponesimod, a Selective S1P1 Receptor Modulator, in Healthy Male Subjects.Mitigation of Initial Cardiodynamic Effects of the S1P1 Receptor Modulator Ponesimod Using a Novel Up-Titration Regimen.Dysregulation of sphingolipid metabolism contributes to bortezomib-induced neuropathic pain.Regulation of Immune Cell Migration by Sphingosine-1-PhosphateA selective inhibitor of ceramide synthase 1 reveals a novel role in fat metabolismAn insight into new strategies to combat antifungal drug resistance
P2860
Q26738344-2B7AD734-2CC3-4D9A-94DD-ED7442D85A2FQ27026175-FDDDC53C-AE8A-45D3-9F3E-5F7922EDF61FQ27939129-2FE5A8A0-A635-4431-93A1-1AFACFEC3A38Q28081129-6E2913B4-CF7F-43EB-BF77-8E386C33AEC6Q28546716-CEE4F73F-429A-4175-9392-35FACFC02F21Q28548390-C20458B8-94EB-4B88-8437-054F8BB51C87Q28555184-6F8832F4-13C8-469B-A06A-F2EFCEA2EF06Q30277138-1C5D4BBE-142A-4DEB-8254-55080C5BDB83Q30300203-D5270D28-186E-4913-83D0-D653284EDD77Q30366282-4FE527B7-FBA6-4DBE-A5F7-F337A3565CB2Q33593619-998C28D4-E0B5-4593-B19D-B48F745F9AFEQ33795328-EAB2AE68-7011-4738-8905-FD18C4B149BDQ33947251-17C10840-D3F9-4FF9-B869-5381009D5392Q34565310-ECC88F29-F7BC-41CD-9E31-DDFAA8A7B709Q35249824-23A3250D-4DB7-4283-969B-C0C4AE53C09BQ35807339-38821407-2EDE-4ED7-8839-1F9B47FB05A9Q36240870-FCEF56D8-B492-4CC7-90C0-0D54057EDA90Q36280060-4FCFFD55-C474-47DA-AB1C-B90EC3DEC88FQ36708344-94EE1712-D131-40EB-A98A-51B4B1D947B6Q38247457-9403AED1-92F7-4458-83DF-AE3146FB5FAFQ38707720-71E8CBD6-A9AA-43E9-A2FA-C7EA8C8011C2Q38774697-6A5E0A70-942C-4453-A7FE-B30793B6F635Q38833311-C54706F1-6E3A-4497-A90D-377D9BEAC847Q38909416-BAB6751E-5CC2-49E1-AC0F-70498220FAF4Q38915115-E965CBF3-2418-4AF7-9A0B-248B50CC90C3Q39152899-8479166E-C11B-439F-8C4D-BC71CE558706Q39172652-845065B0-685D-47EF-BB2A-66D557C18312Q39313715-030EDEDD-ED8A-4204-AAC0-39D3B08B5515Q39379449-39676E35-59B2-4A97-8F17-BCD1AA1975F3Q42174998-ADD3A28E-C1D1-4112-AEC5-7B3699D20917Q45060476-71EFF77A-53F9-4241-A04F-422D96C7B4A9Q45288581-7BE7DAF1-2087-49A8-8E9A-EA41D7895175Q47285240-8483100F-0C73-4A33-BD65-84A2DCF6E7CFQ47430919-954D1D21-B9EC-4E56-9763-19675CA10D50Q48237090-F506A3D1-5F99-4457-BE3C-B70BDC5C0FDEQ51552299-893559BF-9840-4C28-9851-D34EC370FCBAQ52691981-083479FE-2F3C-41B6-AF1D-132EA63F0A3FQ57302349-A75E331F-1E10-459D-B48A-ED2B2A53A042Q58488814-086E4809-84A8-4BE5-A447-CFE9760E8D60Q59135042-241DAD0F-5F40-42ED-9E2D-7E93BE526C42
P2860
Second generation S1P pathway modulators: research strategies and clinical developments.
description
2013 nî lūn-bûn
@nan
2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Second generation S1P pathway modulators: research strategies and clinical developments.
@ast
Second generation S1P pathway modulators: research strategies and clinical developments.
@en
type
label
Second generation S1P pathway modulators: research strategies and clinical developments.
@ast
Second generation S1P pathway modulators: research strategies and clinical developments.
@en
prefLabel
Second generation S1P pathway modulators: research strategies and clinical developments.
@ast
Second generation S1P pathway modulators: research strategies and clinical developments.
@en
P2093
P1476
Second generation S1P pathway modulators: research strategies and clinical developments
@en
P2093
Andreas Billich
Danilo Guerini
Marc Bigaud
Volker Brinkmann
P304
P356
10.1016/J.BBALIP.2013.11.001
P407
P577
2013-11-12T00:00:00Z